IMG_20260712_000217_783.jpg
Also positive for rings and schizonts of plasmodium vivax
I'll analyze this CBC report and the peripheral smear findings for Plasmodium vivax together. Let me pull up the relevant medical information.
Reading File
Now let me search the medical library for P. vivax management alongside the CBC findings in parallel.
Finding Sources
Finding Sources
Good. Now let me pull the specific treatment protocols and CBC interpretation for malaria in parallel.
Reading File
Finding Sources
Now let me read the vivax treatment dosing details and the Harrison's malaria section for a full clinical picture:
Reading File
Finding Sources
I now have all the information needed. Here is a full clinical analysis:
CBC + Peripheral Smear Analysis: Plasmodium vivax Malaria
Patient: Mr. Sushant Dubey | 22 years, Male | Sample: 11 July 2026
CBC Findings - What Is Abnormal and Why
| Parameter | Result | Reference | Status | Clinical Significance |
|---|---|---|---|---|
| Haemoglobin | 12.40 g/dL | 13-18 | Low | Mild anaemia from RBC destruction by parasites |
| Packed Cell Volume | 33.22% | 35-60% | Low | Confirms anaemia |
| MCV | 56.21 fL | 76-97 fL | Very low | Microcytic - likely co-existing iron deficiency |
| MCH | 20.98 pg | 27-31 pg | Low | Hypochromic - supports iron deficiency |
| MCHC | 37.33% | 33-37% | Borderline high | |
| Platelet Count | 93,000/cumm | 1,50,000-4,50,000 | Significantly LOW | Malaria-associated thrombocytopenia |
| RDW | 19.30% | 11.5-16.5% | High | Anisocytosis - mixed picture (malaria + iron deficiency) |
| WBC | 7,400/cumm | 4,000-11,000 | Normal | |
| Differential | Within normal limits | - | Normal |
Key Interpretation
1. Thrombocytopenia (platelets = 93,000)
This is a hallmark finding in P. vivax infection. Thrombocytopenia in vivax malaria can be severe and is caused by:
- Immune-mediated platelet destruction (antibody-antigen complexes)
- Hypersplenism (spleen sequesters platelets)
- Platelet consumption
- Reduced thrombopoiesis due to bone marrow suppression
Per the Red Book 2021, thrombocytopenia is listed as a recognized complication specifically associated with P. vivax, and can occasionally be severe.
2. Peripheral Smear: Rings and Schizonts of P. vivax
- Ring stage (early trophozoite): Large rings, often with 2 chromatin dots; the infected RBC is enlarged (a key feature distinguishing vivax from falciparum)
- Schizonts: Presence of schizonts in peripheral blood is more typical of P. vivax (falciparum schizonts are usually sequestered). Vivax schizonts contain 12-24 merozoites arranged around a central malaria pigment clump (Schuffner's dots in infected RBCs)
- The smear confirms active, ongoing erythrocytic cycle
3. Microcytic Hypochromic Anaemia (MCV 56, MCH 21, RDW 19.3%)
This pattern (very low MCV, high RDW) points to a co-existing iron deficiency anaemia or possibly thalassaemia trait, separate from the malaria-related anaemia. Malaria itself typically causes normocytic anaemia. The microcytosis and raised RDW suggest mixed deficiency - malaria has unmasked or worsened an underlying iron deficiency.
Treatment Protocol (India - National Guidelines)
Per Park's Textbook of Preventive and Social Medicine:
Drug Schedule for P. vivax (adult, ≥15 years):
| Drug | Dose | Timing |
|---|---|---|
| Chloroquine (CQ) 150 mg base tablets | 10 mg/kg (4 tablets) | Day 1 |
| Chloroquine | 10 mg/kg (4 tablets) | Day 2 |
| Chloroquine | 5 mg/kg (2 tablets) | Day 3 |
| Primaquine (PQ) 2.5 mg tablets | 0.25 mg/kg/day (6 tablets/day) | Days 1-14 |
Total chloroquine dose = 25 mg/kg over 3 days - Park's Textbook, p. 307
Primaquine is given for 14 days to eradicate hypnozoites (dormant liver stage) and prevent relapse. Vivax relapse rate in India is ~30% without primaquine. The 14-day course must be given under supervision.
MANDATORY before Primaquine: Check G6PD status - primaquine causes severe haemolytic anaemia in G6PD-deficient patients. Signs of haemolysis to watch for: dark urine, jaundice, abdominal pain, bluish discolouration of lips.
Additional Management
- Antipyretics for fever (paracetamol preferred)
- Investigate for iron deficiency: Serum ferritin, serum iron, TIBC - given the striking microcytosis (MCV 56) which is too low for malaria alone
- Monitor platelets - currently 93,000 (not yet at bleeding risk, but needs monitoring). No specific platelet transfusion needed unless <20,000 or active bleeding
- Repeat CBC after completion of chloroquine (5-7 days) to ensure platelet recovery and haemoglobin stabilization
- Hepatic hypnozoite eradication with primaquine prevents future relapses (which can occur for up to 3 years without treatment)
- If patient does not respond within 72 hours of chloroquine, consider chloroquine resistance - rare in India but documented
Summary
This 22-year-old male has confirmed P. vivax malaria with:
- Active parasitaemia (rings + schizonts on smear)
- Malaria-associated thrombocytopenia (93,000) - expected and will recover with treatment
- Mild anaemia with a microcytic/hypochromic pattern suggesting concurrent iron deficiency (needs separate evaluation)
- Normal WBC and differential
Treatment: Chloroquine 25 mg/kg over 3 days + Primaquine 0.25 mg/kg/day x 14 days (after confirming normal G6PD). The platelet count and anaemia should both improve with successful parasite clearance.
This is a shared conversation. Sign in to Orris to start your own chat.